MX2016015172A - Nueva cepa de lactobacilus casei con capacidad para degradar el peptido inmunotoxico del gluten. - Google Patents

Nueva cepa de lactobacilus casei con capacidad para degradar el peptido inmunotoxico del gluten.

Info

Publication number
MX2016015172A
MX2016015172A MX2016015172A MX2016015172A MX2016015172A MX 2016015172 A MX2016015172 A MX 2016015172A MX 2016015172 A MX2016015172 A MX 2016015172A MX 2016015172 A MX2016015172 A MX 2016015172A MX 2016015172 A MX2016015172 A MX 2016015172A
Authority
MX
Mexico
Prior art keywords
gluten
ability
lactobacillus casei
degrade
gliadin
Prior art date
Application number
MX2016015172A
Other languages
English (en)
Inventor
ALVAREZ SIEIRO Patricia
Cruz Martín Martín María
Redruello Trelles Begoña
LADERO LOSADA Víctor
FERNÁNDEZ GARCÍA María
Ángel Álvarez Gonzalez Miguel
Original Assignee
Consejo Superior De Investig Científicas (Csic)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior De Investig Científicas (Csic) filed Critical Consejo Superior De Investig Científicas (Csic)
Publication of MX2016015172A publication Critical patent/MX2016015172A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei

Abstract

La presente invención se refiere a una cepa bacteriana, Lactobacillus casei IPLA12038 con número de depósito CECT 8590, y su uso para la degradación de gluten, gliadina o sus péptidos derivados. La cepa ha sido aislada de una masa ácida utilizada para la elaboración de pan. Sus ventajas incluyen la capacidad de utilizar la gliadina como fuente de nitrógeno, poseer actividades peptidasa implicadas en la degradación de la misma y ser capaz de degradar completamente el péptido inmunotóxico de 33 aminoácidos implicado en el desencadenamiento de la enfermedad celíaca en un corto período de tiempo. El hecho de considerarla un microorganismo GRAS y QPS, aislado de un alimento fermentado, sensible a agentes antimicrobianos y resistente a las condiciones gastrointestinales analizadas in vitro, garantiza su uso como probiótico o suplemento nutracéutico.
MX2016015172A 2014-05-23 2015-05-22 Nueva cepa de lactobacilus casei con capacidad para degradar el peptido inmunotoxico del gluten. MX2016015172A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430768 2014-05-23
PCT/EP2015/061467 WO2015177366A1 (en) 2014-05-23 2015-05-22 New strain of lactobacillus casei with ability to degrade the immunotoxic peptide from gluten

Publications (1)

Publication Number Publication Date
MX2016015172A true MX2016015172A (es) 2017-03-23

Family

ID=53189844

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015172A MX2016015172A (es) 2014-05-23 2015-05-22 Nueva cepa de lactobacilus casei con capacidad para degradar el peptido inmunotoxico del gluten.

Country Status (9)

Country Link
US (1) US20170196918A1 (es)
EP (1) EP3146037B1 (es)
AU (1) AU2015261774A1 (es)
CA (1) CA2949321A1 (es)
DK (1) DK3146037T3 (es)
EA (1) EA201692035A1 (es)
ES (1) ES2678395T3 (es)
MX (1) MX2016015172A (es)
WO (1) WO2015177366A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3622298A1 (en) * 2017-05-12 2020-03-18 Laboratory Corporation of America Holdings Compositions and methods to detect non-coeliac gluten sensitivity
US20230128187A1 (en) 2019-12-23 2023-04-27 Evonik Operations Gmbh Bacterial consortium comprising at least one bacillus and lactobacillus strain for gluten degradation
EP4081631A1 (en) * 2019-12-23 2022-11-02 Evonik Operations GmbH Process to identify consortia of probiotic strains suitable for gluten degradation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545160B1 (en) * 2010-03-12 2018-07-18 Compagnie Gervais Danone Lactic acid bacteria for coeliac disease

Also Published As

Publication number Publication date
CA2949321A1 (en) 2015-11-26
EP3146037B1 (en) 2018-04-18
US20170196918A1 (en) 2017-07-13
WO2015177366A1 (en) 2015-11-26
DK3146037T3 (en) 2018-07-30
ES2678395T3 (es) 2018-08-10
AU2015261774A1 (en) 2016-11-17
EP3146037A1 (en) 2017-03-29
EA201692035A1 (ru) 2017-04-28

Similar Documents

Publication Publication Date Title
PH12018502714A1 (en) Nicotine particles and compositions
EP4014982A3 (en) Composition for inducing proliferation or accumulation of regulatory t cells
AU2010269814A8 (en) Heat resistant probiotic compositions and healthy food comprising them
AU2011206532A8 (en) Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)
MX2017016283A (es) Lactobacillus paracasei para la produccion de acido linoleico conjugado, preparaciones nutricionales y farmaceuticas que lo contienen y sus usos.
MX339951B (es) Bacillus subtilis aislado de maiz.
MX2015000338A (es) Novedosa cepa de lactobacillus crispatus.
SG11201804006QA (en) Novel peptide
NZ724640A (en) Dough and bread improver
MY193248A (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
MX2017008934A (es) Método para obtener un aislado de péptidos a partir de una biomasa de microalgas enriquecidas en proteínas.
MX2021009398A (es) Composiciones probioticas que comprenden cepas de lactobacillus reuteri y metodos de uso.
MX2016015172A (es) Nueva cepa de lactobacilus casei con capacidad para degradar el peptido inmunotoxico del gluten.
MX2017007654A (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas.
WO2020008149A8 (fr) Utilisation d'une souche de roseburia intestinalis pour la prévention et le traitement de l'inflammation de l'intestin
WO2020091179A3 (ko) 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
MX2020006510A (es) Peptido novedoso.
AU2019263623A8 (en) Probiotic Bifidobacterium breve strain and compositions comprising said strain
GB201905386D0 (en) Probiotic compositions and uses thereof
NZ702936A (en) Gluten-related disorders
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
MX2018006610A (es) Nuevos peptidos que tienen actividad antimicrobiana y nueva enzima capaces de convertir un residuo de configuracion l en un aminoacido de configuracion d en un peptido.
PL3547851T3 (pl) L. salivarius sgl03: właściwości probiotyczne i wytwarzanie przeciwdrobnoustrojowych białek
MX2018012312A (es) Lactobacillus rhamnosus para su uso en la preparacion de productos fermentados.